The Burden of Metastatic Cancer–Induced Bone Pain: A Narrative Review

References

• Body JJ, Quinn G, Talbot S, et al. Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases. Crit Rev Oncol Hematol. 2017;115:67–80. doi:10.1016/j.critrevonc.2017.04.008
   PubMed Web of Science ®Google Scholar
• Hernandez RK, Adhia A, Wade SW, et al. Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clin Epidemiol. 2015;7:335–345. doi:10.2147/CLEP.S85496
   PubMed Web of Science ®Google Scholar
• Ziu E, Viswanathan VK, Mesfin FB. Spinal Metastases. Treasure Island, FL: StatPearls Publishing; 2020.
   Google Scholar
• American Cancer Society. Managing symptoms of bone metastases. American Cancer Society; 2016. Available from: https://www.cancer.org/treatment/understanding-your-diagnosis/advanced-cancer/bone-metastases.html. Accessed September 1, 2020.
   Google Scholar
• Mantyh PW. Bone cancer pain: from mechanism to therapy. Curr Opin Support Palliat Care. 2014;8(2):83–90. doi:10.1097/SPC.0000000000000048
   PubMed Web of Science ®Google Scholar
• Cleeland C, von Moos R, Walker MS, et al. Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. Support Care Cancer. 2016;24(8):3557–3565. doi:10.1007/s00520-016-3154-x
   PubMed Web of Science ®Google Scholar
• Laird BJ, Walley J, Murray GD, et al. Characterization of cancer-induced bone pain: an exploratory study. Support Care Cancer. 2011;19(9):1393–1401. doi:10.1007/s00520-010-0961-3
   PubMed Web of Science ®Google Scholar
• Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):191. doi:10.1093/annonc/mdy152
   Web of Science ®Google Scholar
• Sindhi V, Erdek M. Interventional treatments for metastatic bone cancer pain. Pain Manag. 2019;9(3):307–315. doi:10.2217/pmt-2018-0073
   PubMed Web of Science ®Google Scholar
• Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol. 2014;32(16):1647–1654. doi:10.1200/JCO.2013.51.7219
   PubMed Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P, et al. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage. 2004;28(5):505–510. doi:10.1016/j.jpainsymman.2004.02.024
   PubMed Web of Science ®Google Scholar
• Gater A, Abetz-Webb L, Battersby C, et al. Pain in castration-resistant prostate cancer with bone metastases: a qualitative study. Health Qual Life Outcomes. 2011;12(9):88. doi:10.1186/1477-7525-9-88
   Web of Science ®Google Scholar
• Habberstad R, Frøseth TCS, Aass N, et al. The Palliative Radiotherapy and Inflammation Study (PRAIS) - protocol for a longitudinal observational multicenter study on patients with cancer induced bone pain. BMC Palliat Care. 2018;17(1):110. doi:10.1186/s12904-018-0362-9
   PubMed Web of Science ®Google Scholar
• Smith H. A comprehensive review of rapid-onset opioids for breakthrough pain. CNS Drugs. 2012;26(6):509–535. doi:10.2165/11630580-000000000-00000
   PubMed Web of Science ®Google Scholar
• Dómine Gómez M, Díaz Fernández N, Cantos Sánchez de Ibargüen B, et al. Association of performance status and pain in metastatic bone pain management in the Spanish clinical setting. Adv Ther. 2017;34(1):136–147. doi:10.1007/s12325-016-0435-1
   PubMed Web of Science ®Google Scholar
• Huang JF, Shen J, Li X, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med. 2020;8(7):482. doi:10.21037/atm.2020.03.55
   PubMed Web of Science ®Google Scholar
• Jiang W, Rixiati Y, Zhao B, et al. Incidence, prevalence, and outcomes of systemic malignancy with bone metastases. J Orthop Surg. 2020;28(2):2309499020915989. doi:10.1177/2309499020915989
   Web of Science ®Google Scholar
• Tsuya A, Kurata T, Tamura K, et al. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer. 2007;57(2):229–232. doi:10.1016/j.lungcan.2007.03.013
   PubMed Web of Science ®Google Scholar
• Gong Y, Zhang J, Ji P, et al. Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. Cancer Med. 2018;7(8):4156–4169. doi:10.1002/cam4.1668
   PubMed Web of Science ®Google Scholar
• Autio KA, Bennett AV, Jia X, et al. Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. J Oncol Pract. 2013;9(5):223–229. doi:10.1200/JOP.2013.000876
   PubMedGoogle Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–176. doi:10.1053/ctrv.2000.0210
   PubMed Web of Science ®Google Scholar
• Guerra Liberal FDC, Tavares AAS, Tavares J. Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153. Appl Radiat Isot. 2016;110:87–99. doi:10.1016/j.apradiso.2016.01.003
   PubMed Web of Science ®Google Scholar
• Janjan NA, Payne R, Gillis T, et al. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage. 1998;16(3):171–178. doi:10.1016/S0885-3924(98)00069-4
   PubMed Web of Science ®Google Scholar
• Shinoda Y, Sawada R, Yoshikawa F, et al. Factors related to the quality of life in patients with bone metastases. Clin Exp Metastasis. 2019;36(5):441–448. doi:10.1007/s10585-019-09983-0
   PubMed Web of Science ®Google Scholar
• Janssen SJ, Pereira NRP, Thio Q, et al. Physical function and pain intensity in patients with metastatic bone disease. J Surg Oncol. 2019;120(3):376–381. doi:10.1002/jso.25510
   PubMed Web of Science ®Google Scholar
• Japan Society of Clinical Oncology. Bone metastasis clinical practice guidelines [article in Japanese]; 2015. Available from: https://minds.jcqhc.or.jp/n/med/4/med0203/G0000748/0001. Accessed January 5, 2020.
   Google Scholar
• Lutz S, Chow E. A review of recently published radiotherapy treatment guidelines for bone metastases: contrasts or convergence? J Bone Oncol. 2012;1(1):18–23. doi:10.1016/j.jbo.2012.04.002
   PubMed Web of Science ®Google Scholar
• Van Poznak CH, Temin S, Yee GC, et al. American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29(9):1221–1227. doi:10.1200/JCO.2010.32.5209
   PubMed Web of Science ®Google Scholar
• NCCN, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Adult Cancer Pain. V.1.2020.
   Google Scholar
• Jara C, Del Barco S, Grávalos C, et al. SEOM clinical guideline for treatment of cancer pain (2017). Clin Transl Oncol. 2018;20(1):97–107. doi:10.1007/s12094-017-1791-2
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Organization guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization; 2019. Available from: https://www.who.int/publications/i/item/who-guidelines-for-the-pharmacological-and-radiotherapeutic-management-of-cancer-pain-in-adults-and-adolescents. Accessed October 9, 2020.
   Google Scholar
• Anekar AA, Cascella M. World Health Organization analgesic ladder. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2020, StatPearls Publishing LLC; 2020.
   Google Scholar
• Koufopoulou C, Mosa E, Charalampakis N, et al. Evaluation of quality of life outcomes following palliative radiotherapy in bone metastases: a literature review. J BUON. 2019;24(5):1747–1760.
   PubMed Web of Science ®Google Scholar
• Faris A, Expósito J, Martínez-única A, et al. The efficacy of three-dimensional conformal radiation therapy on pain and quality of life in patients with painful bone metastases: a prospective study. Croat Med J. 2020;61(3):215–222. doi:10.3325/cmj.2020.61.215
   PubMed Web of Science ®Google Scholar
• Arias F, Arrarás JI, Asín G, et al. To what extent does radiotherapy improve the quality of life of patients with bone metastasis? A prospective, single-institutional study. Am J Clin Oncol. 2018;41(2):163–166. doi:10.1097/COC.0000000000000249
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Autorino R, Ciardiello F, et al. External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life. Oncol Rep. 2003;10(2):399–404.
   PubMed Web of Science ®Google Scholar
• McDonald R, Chow E, Rowbottom L, et al. Quality of life after palliative radiotherapy in bone metastases: a literature review. J Bone Oncol. 2015;4(1):24–31. doi:10.1016/j.jbo.2014.11.001
   PubMed Web of Science ®Google Scholar
• Caissie A, Zeng L, Nguyen J, et al. Assessment of health-related quality of life with the European Organization for Research and Treatment of Cancer QLQ-C15-PAL after palliative radiotherapy of bone metastases. Clin Oncol. 2012;24(2):125–133. doi:10.1016/j.clon.2011.08.008
   Web of Science ®Google Scholar
• Conway JL, Yurkowski E, Glazier J, et al. Comparison of patient-reported outcomes with single versus multiple fraction palliative radiotherapy for bone metastasis in a population-based cohort. Radiother Oncol. 2016;119(2):202–207. doi:10.1016/j.radonc.2016.03.025
   PubMed Web of Science ®Google Scholar
• Westhoff PG, Verdam MGE, Oort FJ, et al. Course of quality of life after radiation therapy for painful bone metastases: a detailed analysis from the Dutch bone metastasis study. Int J Radiat Oncol Biol Phys. 2016;95(5):1391–1398. doi:10.1016/j.ijrobp.2016.03.032
   PubMed Web of Science ®Google Scholar
• Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7(1):4–12. doi:10.1016/j.prro.2016.08.001
   PubMed Web of Science ®Google Scholar
• Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 SUPPL):e455S–e497S. doi:10.1378/chest.12-2366
   PubMed Web of Science ®Google Scholar
• Nguyen J, Chow E, Zeng L, et al. Palliative response and functional interference outcomes using the brief pain inventory for spinal bony metastases treated with conventional radiotherapy. Clin Oncol. 2011;23(7):485–491. doi:10.1016/j.clon.2011.01.507
   PubMed Web of Science ®Google Scholar
• Zeng L, Chow E, Bedard G, et al. Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BM22. Int J Radiat Oncol Biol Phys. 2012;84(3):e337–342. doi:10.1016/j.ijrobp.2012.05.028
   PubMed Web of Science ®Google Scholar
• Zeng L, Chow E, Zhang L, et al. Comparison of pain response and functional interference outcomes between spinal and non-spinal bone metastases treated with palliative radiotherapy. Support Care Cancer. 2012;20(3):633–639. doi:10.1007/s00520-011-1144-6
   PubMed Web of Science ®Google Scholar
• Kurosaka S, Satoh T, Chow E, et al. EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy. Ann Nucl Med. 2012;26(6):485–491. doi:10.1007/s12149-012-0598-z
   PubMed Web of Science ®Google Scholar
• Lange R, Overbeek F, de Klerk JM, et al. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. Nuklearmedizin. 2016;55(5):188–195. doi:10.3413/Nukmed-0828-16-05
   PubMedGoogle Scholar
• Xiang Z, Wang L, Yan H, et al. (125) I seed brachytherapy versus external beam radiation therapy for the palliation of painful bone metastases of lung cancer after one cycle of chemotherapy progression. Onco Targets Ther. 2018;11:5183–5193. doi:10.2147/OTT.S154973
   PubMed Web of Science ®Google Scholar
• Yang Z, Tan J, Zhao R, et al. Clinical investigations on the spinal osteoblastic metastasis treated by combination of percutaneous vertebroplasty and (125)I seeds implantation versus radiotherapy. Cancer Biother Radiopharm. 2013;28(1):58–64. doi:10.1089/cbr.2012.1204
   PubMed Web of Science ®Google Scholar
• Wang W, Liu Z, Zhu J, et al. Brachytherapy with iodine 125 seeds for bone metastases. J Cancer Res Ther. 2017;13(5):742–747. doi:10.4103/jcrt.JCRT_399_17
   PubMed Web of Science ®Google Scholar
• Swarm RA, Paice JA, Anghelescu DL, et al. Adult cancer pain, version 3.2019. J Natl Compr Canc Netw. 2019;17(8):977–1007.
   PubMed Web of Science ®Google Scholar
• Deandrea S, Corli O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014;47(1):57–76. doi:10.1016/j.jpainsymman.2013.02.015
   PubMed Web of Science ®Google Scholar
• van den Beuken-van Everdingen M.H., Hochstenbach, L. M., Joosten, E. A., Tjan-Heijnen, V.C., Janssen, D. J. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070–1090.e9. doi:10.1016/j.jpainsymman.2015.12.340
   PubMed Web of Science ®Google Scholar
• Edmonds KP, Saunders IM, Willeford A, et al. Emerging challenges to the safe and effective use of methadone for cancer-related pain in paediatric and adult patient populations. Drugs. 2020;80(2):115–130. doi:10.1007/s40265-019-01234-6
   PubMed Web of Science ®Google Scholar
• Mitera G, Zeiadin N, Kirou-Mauro A, et al. Retrospective assessment of cancer pain management in an outpatient palliative radiotherapy clinic using the pain management index. J Pain Symptom Manage. 2010;39(2):259–267. doi:10.1016/j.jpainsymman.2009.07.005
   PubMed Web of Science ®Google Scholar
• Kirou-Mauro AM, Hird A, Wong J, et al. Has pain management in cancer patients with bone metastases improved? A seven-year review at an outpatient palliative radiotherapy clinic. J Pain Symptom Manage. 2009;37(1):77–84. doi:10.1016/j.jpainsymman.2007.12.014
   PubMed Web of Science ®Google Scholar
• Vieira C, Fragoso M, Pereira D, et al. Pain prevalence and treatment in patients with metastatic bone disease. Oncol Lett. 2019;17(3):3362–3370.
   PubMed Web of Science ®Google Scholar
• Body JJ, von Moos R, Rider A, et al. A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe. J Bone Oncol. 2019;14:100212. doi:10.1016/j.jbo.2018.100212
   PubMed Web of Science ®Google Scholar
• Decroisette C, Monnet I, Berard H, et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol. 2011;6(3):576–582. doi:10.1097/JTO.0b013e318206a1e3
   PubMed Web of Science ®Google Scholar
• von Moos R, Body -J-J, Egerdie B, et al. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Support Care Cancer. 2016;24(3):1327–1337. doi:10.1007/s00520-015-2908-1
   PubMed Web of Science ®Google Scholar
• Uemura H, DiBonaventura M, Wang E, et al. The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use. Expert Rev Pharmacoecon Outcomes Res. 2017;17(5):511–517. doi:10.1080/14737167.2017.1300530
   PubMed Web of Science ®Google Scholar
• Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, et al. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med. 2017;31(1):5–25. doi:10.1177/0269216316639793
   PubMed Web of Science ®Google Scholar
• Hendriks LE, Hermans BC, van den Beuken-van Everdingen MH, et al. Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: a systematic review. J Thorac Oncol. 2016;11(2):155–173. doi:10.1016/j.jtho.2015.10.001
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613–2621. doi:10.1002/cncr.20308
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol. 2003;21(16):3150–3157. doi:10.1200/JCO.2003.04.105
   PubMed Web of Science ®Google Scholar
• Facchini G, Caraglia M, Santini D, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res. 2007;26(3):307–312.
   PubMed Web of Science ®Google Scholar
• Ishiwata T, Hirose T, Hirama M, et al. A feasibility study of zoledronic acid combined with carboplatin/nedaplatin plus paclitaxel in patients with non-small cell lung cancer with bone metastases. Tumori. 2011;97(5):568–572. doi:10.1177/030089161109700505
   PubMed Web of Science ®Google Scholar
• Longo F, Del Signore E, De Sanctis R, et al. Zoledronic acid and treatment of bone metastasis in patients with advanced lung cancer (NSCLC and SCLC). Ann Oncol. 2008;19(S8):viii258.
   Google Scholar
• Del Signore E, De Marinis F. Zoledronic acid role in SREs prevention: an advantage for all patients with advanced NSCLC and bone metastases? J Thorac Oncol. 2012;7(6):S78.
   Web of Science ®Google Scholar
• Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347–2357. doi:10.1200/JCO.2012.47.7901
   PubMed Web of Science ®Google Scholar
• Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965–976. doi:10.1016/j.ijrobp.2010.11.026
   PubMed Web of Science ®Google Scholar
• Hackbarth CB, Vogl TJ, Naguib N, et al. Long-term evaluation of pain reduction after vertebroplasty and kyphoplasty. Acta Radiol Open. 2021;10(7):20584601211028994. doi:10.1177/20584601211028994
   Web of Science ®Google Scholar
• Sadeghi-Naini M, Aarabi S, Shokraneh F, et al. Vertebroplasty and kyphoplasty for metastatic spinal lesions: a systematic review. Clin Spine Surg. 2018;31(5):203–210. doi:10.1097/BSD.0000000000000601
   PubMed Web of Science ®Google Scholar
• Bao L, Jia P, Li J, et al. Percutaneous vertebroplasty relieves pain in cervical spine metastases. Pain Res Manag. 2017;2017:3926318. doi:10.1155/2017/3926318
   PubMed Web of Science ®Google Scholar
• Mezrich JL, Resnik CS. Panacea or sham? Legal issues of vertebroplasty. J Am Coll Radiol. 2016;13(6):663–665. doi:10.1016/j.jacr.2016.02.006
   PubMed Web of Science ®Google Scholar
• Yildizhan S, Boyaci MG, Rakip U, et al. Role of radiofrequency ablation and cement injection for pain control in patients with spinal metastasis. BMC Musculoskelet Disord. 2021;22(1):912. doi:10.1186/s12891-021-04799-0
   PubMed Web of Science ®Google Scholar
• Biermann JS, Holt GE, Lewis VO, et al. Metastatic bone disease: diagnosis, evaluation, and treatment. J Bone Joint Surg Am. 2009;91(6):1518–1530.
   PubMed Web of Science ®Google Scholar
• Nooh A, Goulding K, Isler MH, et al. Early improvement in pain and functional outcome but not quality of life after surgery for metastatic long bone disease. Clin Orthop Relat Res. 2018;476(3):535–545. doi:10.1007/s11999.0000000000000065
   PubMed Web of Science ®Google Scholar
• Sugiura H, Yamada K, Sugiura T, et al. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 2008;466(3):729–736. doi:10.1007/s11999-007-0051-0
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs. 2001;61(9):1253–1274. doi:10.2165/00003495-200161090-00003
   PubMed Web of Science ®Google Scholar
• Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34(14):1652–1659. doi:10.1200/JCO.2015.65.7270
   PubMed Web of Science ®Google Scholar
• ALMouaalamy N. Opioid-induced constipation in advanced cancer patients. Cureus. 2021;13(4):e14386. doi:10.7759/cureus.14386
   PubMed Web of Science ®Google Scholar
• Khan F, Mehan A. Addressing opioid tolerance and opioid-induced hypersensitivity: recent developments and future therapeutic strategies. Pharmacol Res Perspect. 2021;9(3):e00789. doi:10.1002/prp2.789
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev. 2014;2014(5):Cd011056.
   PubMedGoogle Scholar
• Streicher JM, Bilsky EJ. Peripherally acting mu-opioid receptor antagonists for the treatment of opioid-related side effects: mechanism of action and clinical implications. J Pharm Pract. 2018;31(6):658–669. doi:10.1177/0897190017732263
   PubMed Web of Science ®Google Scholar
• Azizoddin DR, Knoerl R, Adam R, et al. Cancer pain self-management in the context of a national opioid epidemic: experiences of patients with advanced cancer using opioids. Cancer. 2021;127:3239–3245. doi:10.1002/cncr.33532
   PubMed Web of Science ®Google Scholar
• Rodrigue D, Winkelmann J, Price M, et al. Opioid misuse: an organizational response while managing cancer-related pain. Clin J Oncol Nurs. 2020;24(2):170–176. doi:10.1188/20.CJON.170-176
   PubMed Web of Science ®Google Scholar
• Rosner B, Neicun J, Yang JC, et al. Opioid prescription patterns in Germany and the global opioid epidemic: systematic review of available evidence. PLoS One. 2019;14(8):e0221153. doi:10.1371/journal.pone.0221153
   PubMed Web of Science ®Google Scholar
• Fischer B, Daldegan-Bueno COK-M, Daldegan-Bueno D, et al. Why comparative epidemiological indicators suggest that New Zealand is unlikely to experience a severe opioid epidemic. Int J Drug Policy. 2021;93:103166. doi:10.1016/j.drugpo.2021.103166
   PubMed Web of Science ®Google Scholar
• Singh B, Rao R. PerspectivesIs there an opioid epidemic in India? J Public Health. 2021;43((Suppl 2)):ii43–ii50. doi:10.1093/pubmed/fdab322
   Web of Science ®Google Scholar
• Ziegler LE, Craigs CL, West RM, et al. Is palliative care support associated with better quality end-of-life care indicators for patients with advanced cancer? A retrospective cohort study. BMJ Open. 2018;8(1):e018284. doi:10.1136/bmjopen-2017-018284
   PubMed Web of Science ®Google Scholar
• Chapman EJ, Edwards Z, Boland JW, et al. Practice review: evidence-based and effective management of pain in patients with advanced cancer. Palliat Med. 2020;34(4):444–453. doi:10.1177/0269216319896955
   PubMed Web of Science ®Google Scholar
• Hao D, Sidharthan S, Cotte J, et al. Interventional therapies for pain in cancer patients: a narrative review. Curr Pain Headache Rep. 2021;25(7):44. doi:10.1007/s11916-021-00963-2
   PubMed Web of Science ®Google Scholar
• Gress KL, Charipova K, Kaye AD, et al. An overview of current recommendations and options for the management of cancer pain: a comprehensive review. Oncol Ther. 2020;8(2):251–259. doi:10.1007/s40487-020-00128-y
   PubMed Web of Science ®Google Scholar
• Degnan M, Mousa SA. A narrative review of buprenorphine in adult cancer pain. Expert Rev Clin Pharmacol. 2020;13(10):1159–1167. doi:10.1080/17512433.2020.1822163
   PubMed Web of Science ®Google Scholar
• IARC. Global cancer observatory: GLOBOCAN 2018. International Agency for Research on Cancer. 2018. Available from: https://gco.iarc.fr/. Accessed December 14, 2020.
   Google Scholar
• Guo X, Zhang C, Guo Q, et al. The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer. Cancer Manag Res. 2018;10:1639–1646. doi:10.2147/CMAR.S168579
   PubMed Web of Science ®Google Scholar
• Guo Q, Zhang C, Guo X, et al. Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study. Cancer Manag Res. 2018;10:2935–2944. doi:10.2147/CMAR.S170083
   PubMed Web of Science ®Google Scholar
• Guo X, Zhang C, Ma W, et al. Patterns of bone metastases in newly diagnosed colorectal cancer: a real-world analysis in the SEER database. Int J Colorectal Dis. 2019;34(3):533–543. doi:10.1007/s00384-018-3213-5
   PubMed Web of Science ®Google Scholar
• Christensen TD, Jensen SG, Larsen FO, et al. Systematic review: incidence, risk factors, survival and treatment of bone metastases from colorectal cancer. J Bone Oncol. 2018;13:97–105. doi:10.1016/j.jbo.2018.09.009
   PubMed Web of Science ®Google Scholar